348 related articles for article (PubMed ID: 31134521)
1. Mechanism of Action and Clinical Attributes of Auryxia
Ganz T; Bino A; Salusky IB
Drugs; 2019 Jun; 79(9):957-968. PubMed ID: 31134521
[TBL] [Abstract][Full Text] [Related]
2. Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD.
Yokoyama K; Hirakata H; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Block GA
Clin J Am Soc Nephrol; 2014 Mar; 9(3):543-52. PubMed ID: 24408120
[TBL] [Abstract][Full Text] [Related]
3. Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses.
Block GA; Pergola PE; Fishbane S; Martins JG; LeWinter RD; Uhlig K; Neylan JF; Chertow GM
Nephrol Dial Transplant; 2019 Jul; 34(7):1115-1124. PubMed ID: 30380116
[TBL] [Abstract][Full Text] [Related]
4. Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease.
Francis C; Courbon G; Gerber C; Neuburg S; Wang X; Dussold C; Capella M; Qi L; Isakova T; Mehta R; Martin A; Wolf M; David V
Kidney Int; 2019 Dec; 96(6):1346-1358. PubMed ID: 31668632
[TBL] [Abstract][Full Text] [Related]
5. Effect of Ferric Citrate versus Ferrous Sulfate on Iron and Phosphate Parameters in Patients with Iron Deficiency and CKD: A Randomized Trial.
Womack R; Berru F; Panwar B; Gutiérrez OM
Clin J Am Soc Nephrol; 2020 Sep; 15(9):1251-1258. PubMed ID: 32694162
[TBL] [Abstract][Full Text] [Related]
6. A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.
Block GA; Fishbane S; Rodriguez M; Smits G; Shemesh S; Pergola PE; Wolf M; Chertow GM
Am J Kidney Dis; 2015 May; 65(5):728-36. PubMed ID: 25468387
[TBL] [Abstract][Full Text] [Related]
7. Clinical experience with the use of ferric citrate as a phosphate binder in pediatric dialysis patients.
Hanudel MR; Laster M; Ramos G; Gales B; Salusky IB
Pediatr Nephrol; 2018 Nov; 33(11):2137-2142. PubMed ID: 29956006
[TBL] [Abstract][Full Text] [Related]
8. Ferric citrate spans mineral metabolism and anemia domains in ESRD: a review of efficacy and safety data.
Sinsakul M; Rodby R; Umanath K; Niecestro R; Dwyer JP
Expert Rev Clin Pharmacol; 2014 Nov; 7(6):705-10. PubMed ID: 25242077
[TBL] [Abstract][Full Text] [Related]
9. Administration of Ferric Citrate Hydrate Decreases Circulating FGF23 Levels Independently of Serum Phosphate Levels in Hemodialysis Patients with Iron Deficiency.
Iguchi A; Kazama JJ; Yamamoto S; Yoshita K; Watanabe Y; Iino N; Narita I
Nephron; 2015; 131(3):161-6. PubMed ID: 26551233
[TBL] [Abstract][Full Text] [Related]
10. Effect of ferric citrate hydrate on fibroblast growth factor 23 and platelets in non-dialysis-dependent chronic kidney disease and non-chronic kidney disease patients with iron deficiency anemia.
Ito K; Akizawa T; Arita K; Mitobe Y; Komatsu N
Clin Exp Nephrol; 2024 Jul; 28(7):636-646. PubMed ID: 38402503
[TBL] [Abstract][Full Text] [Related]
11. Role of Ferric Citrate in Hyperphosphatemia and Iron Deficiency Anemia in Non Dialysis CKD Patients.
Nand N; Giri K; Jain D
J Assoc Physicians India; 2019 Apr; 67(4):53-56. PubMed ID: 31311220
[TBL] [Abstract][Full Text] [Related]
12. Iron-based phosphate binders: a paradigm shift in the treatment of hyperphosphatemic anemic CKD patients?
Locatelli F; Del Vecchio L
J Nephrol; 2017 Dec; 30(6):755-765. PubMed ID: 28717990
[TBL] [Abstract][Full Text] [Related]
13. A review of ferric citrate clinical studies, and the rationale and design of the Ferric Citrate and Chronic Kidney Disease in Children (FIT4KiD) trial.
Hanudel MR; Laster ML; Portale AA; Dokras A; Quigley RP; Guzman GAL; Zaritsky JJ; Hayde NA; Kaskel FJ; Mitsnefes MM; Ramirez JA; Imani PD; Srivaths PR; Kogon AJ; Denburg MR; Blydt-Hansen TD; Reyes LZ; Greenbaum LA; Weidemann DK; Warady BA; Elashoff DA; Mendley SR; Isakova T; Salusky IB
Pediatr Nephrol; 2022 Nov; 37(11):2547-2557. PubMed ID: 35237863
[TBL] [Abstract][Full Text] [Related]
14. [Pharmacological profile and clinical findings of a new phosphate binder, ferric citrate hydrate (Riona® Tablets)].
Miyazaki A; Matsuo A; Iida A; Nishino N; Maeda K; Matsumoto Y; Orui S
Nihon Yakurigaku Zasshi; 2014 Dec; 144(6):294-304. PubMed ID: 25492366
[No Abstract] [Full Text] [Related]
15. A Pilot Randomized Trial of Ferric Citrate Coordination Complex for the Treatment of Advanced CKD.
Block GA; Block MS; Smits G; Mehta R; Isakova T; Wolf M; Chertow GM
J Am Soc Nephrol; 2019 Aug; 30(8):1495-1504. PubMed ID: 31278194
[TBL] [Abstract][Full Text] [Related]
16. Novel Oral Iron Therapies for Iron Deficiency Anemia in Chronic Kidney Disease.
Pergola PE; Fishbane S; Ganz T
Adv Chronic Kidney Dis; 2019 Jul; 26(4):272-291. PubMed ID: 31477258
[TBL] [Abstract][Full Text] [Related]
17. Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency.
Iguchi A; Yamamoto S; Yamazaki M; Tasaki K; Suzuki Y; Kazama JJ; Narita I
Clin Exp Nephrol; 2018 Aug; 22(4):789-796. PubMed ID: 29181658
[TBL] [Abstract][Full Text] [Related]
18. Association of fibroblast growth factor 23 and α-klotho in hemodialysis patients during administration of ferric citrate hydrate: post hoc analysis of ASTRIO study.
Ito K; Yokoyama K; Nakayama M; Fukagawa M; Hirakata H
BMC Nephrol; 2021 Nov; 22(1):374. PubMed ID: 34758731
[TBL] [Abstract][Full Text] [Related]
19. Use of phosphate binders in chronic kidney disease.
Ketteler M; Biggar PH
Curr Opin Nephrol Hypertens; 2013 Jul; 22(4):413-20. PubMed ID: 23736841
[TBL] [Abstract][Full Text] [Related]
20. Novel iron-containing phosphate binders and anemia treatment in CKD: oral iron intake revisited.
Nakanishi T; Hasuike Y; Nanami M; Yahiro M; Kuragano T
Nephrol Dial Transplant; 2016 Oct; 31(10):1588-94. PubMed ID: 26142396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
